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Introduction 
Down's syndrome, the most frequent chromosomal
disorder with mental retardation, results from triplicat-
ed chromosome 21, or from a triplication of its restrict-
ed regions. The immune function in individuals with
DS has been shown to be defective [1-3]. Dysregula-
tion of the immune system is one characteristic patho-
logical feature of the syndrome, and leads to increased
susceptibility to viral or bacterial infections and
leukemia. These observations, together with the
demonstration of a frequent occurrence of HBsAg car-
rier state and of autoantibodies, have prompted inves-
tigations of the immune function in DS patients [4]. 
Thymic morphological and functional abnormali-
ties have been also demonstrated [5].
The trisomic chromosome 21 carries genes for
receptors and ligands of the interferon family. In DS
patients, abnormalities in thymus anatomy depend on
interferon-γ (IF-γ) and tumour necrosis factor-α (TNF-
α) overexpression was found [6]. 
Interferon-γ can also cause neurodegeneration and
β-amyloid production in Down syndrome and in its
animal model, the trisomy 16 mouse [7], and accounts
for cognitive impairment. Apolipoprotein E (ApoE) is
a polymorphic protein that plays a central role in plas-
ma lipoprotein metabolism. Its production and accu-
mulation are increased in central nervous system dis-
orders like a Alzheimer´s disease and in DS [8]. DS is
associated with high frequency of celiac disease, a
chronic inflammatory disease of the small intestinal
mucosa. 
Cytokines participate in many physiological
processes including the regulation of immune and
inflammatory responses. These effector molecules are
produced transiently and locally controlling the ampli-
tude and duration of the response. 
IL-4, is a cytokine that induces differentiation of
naive helper T cells (Th0 cells) to Th2 cells. It is a key
regulator in humoral and adaptive immunity [9].
IL-10 is produced primarily by monocytes and to a
lesser extent by lymphocytes. This cytokine has
pleiotropic effects in immunoregulation and inflam-
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mation. It also enhances B cell proliferation, and anti-
body production [10]. It is capable of inhibiting syn-
thesis of pro-inflammatory cytokines like interferon-γ,
interleukin-2, interleukin-3 [10]. 
IL-13 is a cytokine secreted by many cell types, but
especially T helper type 2 (Th2) cells. In addition to
effects on immune cells that are similar to those of the
closely related cytokine IL-4, IL-13 is more impor-
tantly implicated as a central mediator of the physio-
logic changes induced by allergic inflammation in
many tissues[11]. 
Our previous studies suggest an important role of
changes of serum levels of cytokines and lipid peroxi-
dation factors in the pathogenesis of acute and chronic
diseases of the central nervous system [12-15]. 
In the literature there a lot of studies on pro-
inflammatory interleukins (interleukin-1, interleukin-
2, interleukin-6 and interleukin-8) in subjects with DS
[6,16-18] but there are only few data on anti-inflam-
matory cytokines in those subjects [19,20]. The aim of
this study was to evaluate interleukin concentrations
(IL-4, IL-10 and IL-13) in plasma in children with DS. 
Materials and methods
Patients. The study involved 53 children and adolescents, includ-
ing 20 with DS (10 males and 10 females; mean age 8.57±6.19
years; range 5-17). All of them were patients of the Department of
Pediatric Neurology and Rehabilitation, Medical University of
Bia³ystok. All Down syndrome subjects were assessed by clinical
examination and karyotype analysis, they showed a mild and vari-
able degree of mental retardation, were free of other pathological
conditions at the moment of the study and were in good health sta-
tus. We recruited thirty three healthy subjects as controls. The
healthy children were in the age 8-17 years (mean age 12.11±3.46).
There were 22 females and 11 males in this group. Patients with
significantly abnormal basic laboratory findings, indicating liver
dysfunction and with lipid metabolism disorders, were excluded
from the study.
ELISA testing. The patients affected by allergic, inflammatory,
infectious or immune disorders which could interfere with the
study were also excluded. Plasma for analysis of cytokines was
obtained simultaneously with routine laboratory tests. Blood sam-
ples were obtained under a fasting and rest condition, in the morn-
ing. Blood was drawn from the antecubital vein, centrifuged,
frozen and stored until -20°C until the assay. Immunoassay kits of
BioSource (Bio Source Internationallnc. 542 Flynn Road, Camar-
illo, California 93012, USA) were used. Levels of: 1. IL-4, 2. IL-
10 and 3. IL-13 in plasma samples were determined by specific
enzyme- linked immunosorbent assay (ELISA) techniques accord-
ing to manufacturer's instructions (Catalogue numbers: KAP1281,
KAP1321, KPMS113). The minimum detectable concentration of
assay was 1.2 pg/mL for IL-4, 0.2 pg/mL for IL-10 and 0.73 pg/mL
for IL-13. We tested both groups in each assay. Laboratory staff
was blind to clinical data. 
Ethical issues. The protocol was approved by the Ethics Commit-
tee at the Medical University of Bia³ystok.
Statistical analysis. Statistical evaluation was carried out by
means ±SD with software STATISTICA 6.0 PL. 
Results
IL-4 was detectable in 5 out of 20 (25%) subjects with
DS (3.16±1.43 pg/mL) and 10 out of 33 (28.6%)
healthy subjects (3.39±1.44 pg/mL). IL-13 was
detectable in 3 out of 20 (15%) patients with DS
(1.043±0.116 pg/mL) and 5 out of 33 (15.2%)
healthy subjects (1.78±0.79 pg/mL). IL-10 was
detectable in one subject with DS only (7.321
pg/mL) and two healthy children (24.24 pg/mL and
37.68 pg/mL). Cytokine plasma levels are presented
in Tables 1 and 2.
The number of measurable samples was too small
for statistical analysis. Moreover, the data were not
normally distributed. Therefore, we did not find any
significant differences or trends between both studied
groups.
No significant correlations between measurable
cytokine levels and age or gender were found.
Discussion
We examined the interleukins plasma concentrations
from aged individuals with Down syndrome (age 5-17
years old, 10 female, 10 female) in order to correlate
with age and gender. In the present study, we did not
find significant increase of plasma IL-4, IL-10 and IL-
13 concentrations in children with DS compared with
healthy children. We also did not note a correlation
between anti-inflammatory interleukins plasma levels
and age or gender. Weakness of our study was a small
study group and determination of the interleukins in
plasma. In contrast, Guuzzarotti et al [20] found
increase of serum IL-10 concentration in adolescents
with DS. They assessed cytokine production, immune
activation, T lymphocytes maturation, and serum inter-
leukin-7 concentration in 24 adolescents with DS and
42 age- and gender-matched controls. The IF-γ, IL-10
production, as well as serum IL-7 concentrations and
activation markers-bearing T lymphocytes were signif-
icantly increased. The discrepancy in these studies
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Table 1. Selected data of plasma cytokines in children and adoles-
cents with Down syndrome and in control group presented as
mean±SD.
may be due to the differences in the ages of the indi-
viduals studied.
In another study, Park et al. [21] found that cellular
proliferation and IL-2 production in inactivated cells
were not different in adult with DS and controls.
It was previously reported that serum IL-6 levels
from the sporadic type of Alzheimer disease and that
of a similar stage of demented persons with DS were
increased compared with normal age-matched healthy
controls [22].
Griffin et al. [23] demonstrated that brain IL-1
immunoactivity increased in individuals with DS and
Alzheimer disease.
IL-4 was believed to be solely responsible for the
expression of immunoglobulin E the mouse [24,25].
The discovery of interleukin-13 and the demonstra-
tion that this cytokine could also induce immunoglob-
ulin E production by human B cells established that a
further layer of complexity existed in the regulation of
immunoglobulin E [26].
Smooth muscle cells in the tunica media of many
blood vessels also produce IL-6 as a pro-inflamma-
tory cytokine. IL-6 role as an anti-inflammatory
cytokine is mediated through its inhibitory effects on
TNF-alpha and IL-1, and activation of IL-1ra and
IL-10 [27].
Intracranial production of cytokines has been
demonstrated after acute disseminated encephalo-
myelitis [28] and encephalopathy [29]. The cere-
brospinal fluid IL-6, IL-10, TNF-α, and sTNFR1 con-
centration were elevated in the patients with acute dis-
seminated encephalomyelitis. Myelin basic protein
levels in cerebrospinal fluid of the patients with ele-
vated cerebrospinal fluid sTNFR1 levels were signifi-
cantly higher than those in cerebrospinal fluid of the
patients with normal cerebrospinal fluid sTNFR1 lev-
els. It was suggested that IL-6 and TNF-α were medi-
ate inflammation in the central nervous system in acute
disseminated encephalomyelitis [28].
Franciosi et al. [18] demonstrated that IL-8 potenti-
ates the effect of amyloid beta peptide in inducing secre-
tion of inflammatory cytokines from cultured human
microglia, suggesting a possible role in the early devel-
opment of Alzheimer neuropathology in DS.
Inflammation might play a role in the curtailed
growth in DS brains, as it is postulated to do in the
precocious development of Alzheimer pathology in
DS [30].
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Table 2. Clinical characteristic and cytokine levels in patients with Down syndrome, in all of the studied subjects the were no symptoms
of systemic inflammation in clinical examination.
ND – not detectable
In conclusion, present study does not confirm any
changes anti-inflammatory interleukins in plasma
among children with DS. However, our study focused
on few plasma cytokines only. So we could not
exclude immune dysfunction and cytokine levels dis-
turbances in DS. Further studies seems to be necessary. 
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